Harman Finochem Ltd Revenue and Competitors
Estimated Revenue & Valuation
- Harman Finochem Ltd's estimated annual revenue is currently $3.5M per year.
- Harman Finochem Ltd's estimated revenue per employee is $3,928
Employee Data
- Harman Finochem Ltd has 891 Employees.
- Harman Finochem Ltd grew their employee count by 8% last year.
Harman Finochem Ltd's People
Name | Title | Email/Phone |
---|
What Is Harman Finochem Ltd?
Harman Finochem Limited is a professionally managed independent company engaged in manufacturing of Active Pharmaceutical ingredients (API's) and chemical intermediates. The company was established way back in 1983 by Bhupinder Singh Manhas, the CMD of the company. • Manufacturer and Exporter of Active Pharmaceutical Ingredients. • Two manufacturing sites at Aurangabad and one at Vapi with capacity of 350,000 Litres. • Supply of API"s as a Major Thrust Area to Pharma and Generic companies. • Certificate of recognition as 'EXPORT HOUSE' by Government of India. • State of the art manufacturing facilities inspected and complying with cGMP norms as per USFDA, ICH Q7A, TGA, PIC, WHO – GMP, Schedule M and Japanese Foreign Accreditation. • State-of-the-art Quality Control Laboratories with GLP compliance. • cGMP compliance Pilot plant with clean room facility. • Powder processing area with pneumatic controls and Particle Size options: Milling & Micronising. • CRAMs offered.
keywords:N/AN/A
Total Funding
891
Number of Employees
$3.5M
Revenue (est)
8%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Harman Finochem Ltd News
... Divalproex Sodium API 2022 Empresas clave | Dr. Reddy's Laboratories Ltd., SCI PHARMTECH, Anjan Drug Private Limited, Harman Finochem...
API Polpharma · Admiron · Jubilant Pharma · Cemex Pharma · Harman Finochem Limited · RA Chem Pharma Ltd · Guilin Hwasun Pharmacentical · LGM Pharma.
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | N/A | 897 | 24% | N/A |
#2 | $88.3M | 901 | 1% | $296.3M |
#3 | N/A | 901 | 14% | N/A |
#4 | $113.8M | 903 | -4% | N/A |
#5 | $83.5M | 918 | 10% | N/A |